Lexaria Bioscience Corp.
Lexaria Bioscience Corp.
Your view on LEXXW
Overview
What the company does, where it operates, and who runs it.
About Lexaria Bioscience Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard C. Christopher
- Headquarters
- 740 McCurdy Road, Kelowna, NV, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard C. Christopher
- Headquarters
- 740 McCurdy Road, Kelowna, NV, US
Lexaria Bioscience Corp. is a biotechnology firm specializing in the creation and licensing of its patented drug delivery system, DehydraTECH. This innovative technology functions by integrating fat-soluble compounds or active pharmaceutical ingredients (APIs) with particular long-chain fatty acids and specific carrier substances. The aim of this process is to significantly boost their entry into the bloodstream, consequently enhancing their effectiveness, enabling lower overall dosages, and supporting healthier methods of oral consumption. DehydraTECH can be utilized with a broad spectrum of active molecules, including fat-soluble vitamins, pain relievers, hormones, PDE5 inhibitors, antiviral agents, oral nicotine and its analogues, and various cannabinoids. The company is also investigating DehydraTECH's potential therapeutic applications for conditions such as high blood pressure, cardiovascular diseases, and diabetes. Its versatility renders it suitable for integration into diverse product categories, encompassing pharmaceuticals, nutraceuticals, over-the-counter remedies, and consumer packaged goods. Established in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Lexaria Bioscience Corp., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lexaria Bioscience Corp.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lexaria Bioscience Corp.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lexaria Bioscience Corp.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lexaria Bioscience Corp.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lexaria Bioscience Corp. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Lexaria Bioscience Corp., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Lexaria Bioscience Corp. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lexaria Bioscience Corp.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lexaria Bioscience Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lexaria Bioscience Corp.. Press releases and market coverage, newest first.